Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors

Journal of Nuclear Medicine

Volumn 54, Issue 12, 2013, Pages 2032-2038

  Ezziddin, Samer ^a   Sabet, Amir ^a   Logvinski, Timur ^a   Alkawaldeh, Khaled ^a   Yong Hing, Charlotte J ^b   Ahmadzadehfar, Hojjat ^a   Grünwald, Frank ^c   Biersack, Hans Jürgen ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

131I MIBG therapy; Carcinoid tumors; Neuroendocrine tumors; Oncology; Radionuclide therapy; Targeted radiotherapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; (3 IODOBENZYL)GUANIDINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOID; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; KIDNEY FUNCTION TEST; LEUKOPENIA; LIVER FUNCTION TEST; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION RESPONSE; RADIATION SAFETY; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; 131I-MIBG THERAPY; CARCINOID TUMORS; COHORT ANALYSIS; MIDDLE AGED; NEUROENDOCRINE TUMOR; ONCOLOGY; PATHOLOGY; RADIATION DOSE; RADIONUCLIDE THERAPY; TARGETED RADIOTHERAPY; TIME; TREATMENT OUTCOME; CARCINOID TUMOR;

131I-MIBG THERAPY; CARCINOID TUMORS; NEUROENDOCRINE TUMORS; ONCOLOGY; RADIONUCLIDE THERAPY; TARGETED RADIOTHERAPY;

3-IODOBENZYLGUANIDINE; ADULT; AGED; CARCINOID TUMOR; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RADIATION DOSAGE; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893401949     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.119313     Document Type: Article

References (48)

1. Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery. 2003;134:956-962.
2. Gedik GK, Hoefnagel CA, Bais E, Olmos RA. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2008; 35:725-733.
3. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2007;14:569-585.
4. Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131IMIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest. 1997;20:648-658.
5. Hoefnagel CA, Voute PA, De Kraker J, Valdes Olmos RA. [131I]metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma. J Nucl Biol Med. 1991;35:202-206.
6. Garaventa A, Guerra P, Arrighini A, et al. Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine. Cancer. 1991;67:922-928.
7. Ehninger G, Klingebiel T, Kumbier I, et al. Stability and pharmacokinetics of m-[131I]iodobenzylguanidine in patients. Cancer Res. 1987;47:6147-6149.
8. Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med. 1994;21: 545-559.
9. Pasieka JL, McEwan AJ, Rorstad O. The palliative role of 131I-MIBG and 111Inoctreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery. 2004;136:1218-1226.
10. SywakMS, Pasieka JL, McEwan A, Kline G, Rorstad O. 131I-meta- iodobenzylguanidine in the management of metastatic midgut carcinoid tumors. World J Surg. 2004; 28:1157-1162.
11. Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid: results in 98 patients. Cancer. 2004; 101:1987-1993.
12. Gonias S, Goldsby R, Matthay KK, et al. Phase II study of high-dose [131I] metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27:4162-4168.
13. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun. 1992;13:513-521.
14. Kosmin MA, Bomanji JB, Cork NJ, Shankar A, Gaze MN. Hypertension complicating 131I-meta-iodobenzylguanidine therapy for neuroblastoma. Eur J Nucl Med Mol Imaging. 2012;39:597-601.
15. Matthay KK, Weiss B, Villablanca JG, et al. Dose escalation study of no-carrieradded 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. J Nucl Med. 2012;53:1155-1163.
16. Khan MU, Morse M, Coleman RE. Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors. Q J Nucl Med Mol Imaging. 2008;52:441-454.
17. Postema EJ, McEwan AJ. Radioiodinated metaiodobenzylguanidine treatment of neuroendocrine tumors in adults. Cancer Biother Radiopharm. 2009;24:519-525.
18. Grünwald F, Ezziddin S. 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. Semin Nucl Med. 2010;40:153-163.
19. Hoefnagel CA, Den Hartog Jager FC, Van Gennip AH, Marcuse HR, Taal BG. Diagnosis and treatment of a carcinoid tumor using iodine-131 meta-iodobenzylguanidine. Clin Nucl Med. 1986;11:150-152.
20. Castellani MR, Chiti A, Seregni E, Bombardieri E. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours: experience of the National Cancer Institute of Milan. Q J Nucl Med. 2000; 44:77-87.
21. Pathirana AA, Vinjamuri S, Byrne C, Ghaneh P, Vora J, Poston GJ. 131I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome. Eur J Surg Oncol. 2001;27:404-408.
22. Eriksson B, Kloppel G, Krenning E, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors: well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology. 2008;87:8-19.
23. Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H, Beijnen JH. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol. 1996;14:1829-1838.
24. Mukherjee JJ, Kaltsas GA, Islam N, et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I-meta-iodobenzylguanidine. Clin Endocrinol (Oxf). 2001;55: 47-60.
25. Bomanji JB, Wong W, Gaze MN, et al. Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy. Clin Oncol (R Coll Radiol). 2003; 15:193-198.
26. Nwosu AC, Jones L, Vora J, Poston GJ, Vinjamuri S, Pritchard DM. Assessment of the efficacy and toxicity of 131I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours. Br J Cancer. 2008;98:1053-1058.
27. Buscombe JR, Cwikla JB, Caplin ME, Hilson AJ. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl Med Commun. 2005; 26:969-976.
28. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754-2762.
29. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-2130.
30. Ezziddin S, Opitz M, Attassi M, et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2011;38:459-466.
31. Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010;28:1652-1659.
32. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG. Epidemiology and survival in patients with carcinoid disease in The Netherlands: an epidemiological study with 2391 patients. Ann Oncol. 2001;12:1295-1300.
33. Pryma DA, Noto R, Goldsmith SJ, et al. Interim results of an open-label, single-arm trial of ultratrace I-131-iobenguane in patients with metastatic pheochromocytoma/ paraganglioma (Pheo). J Clin Oncol. 2012;30(suppl):e13592.
34. Troncone L, Rufini V. 131I-MIBG therapy of neural crest tumours. Anticancer Res. 1997;17:1823-1831.
35. Sisson JC, Shapiro B, Hutchinson RJ, et al. Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine. Eur J Nucl Med. 1994;21:46-52.
36. Sisson JC, Hutchinson RJ, Carey JE, et al. Toxicity from treatment of neuroblastoma with 131I-meta-iodobenzylguanidine. Eur J Nucl Med. 1988;14:337-340.
37. Matthay KK, Huberty JP, Hattner RS, et al. Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. J Nucl Biol Med. 1991;35:244-247.
38. Lewington VJ, Zivanovic MA, Tristam M, McEwan AJ, Ackery DM. Radiolabelled metaiodobenzylguanidine targeted radiotherapy for malignant phaeochromocytoma. J Nucl Biol Med. 1991;35:280-283.
39. Bongers V, de Klerk JM, Zonnenberg BA, de Kort G, Lips CJ, van Rijk PP. Acute liver necrosis induced by iodine-131-MIBG in the treatment of metastatic carcinoid tumors. J Nucl Med. 1997;38:1024-1026.
40. Forrer F, Waldherr C, Maecke HR, Mueller-Brand J. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res. 2006;26:703-707.
41. Basu B, Sirohi B, Corrie P. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. Endocr Relat Cancer. 2010;17:R75-R90.
42. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23:4897-4904.
43. Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J. A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer. 2001;91:1543-1548.
44. Kulke MH, Kim H, Stuart K, et al. A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest. 2004;22:353-359.
45. Kulke MH, Kim H, Clark JW, et al. A phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer. 2004;101:934-939.
46. Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med. 1994;120:302-309.
47. Ezziddin S, Logvinski T, Yong-Hing C, et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2006;47:223-233.
48. Madsen MT, Bushnell DL, Juweid ME, et al. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model. J Nucl Med. 2006;47:660-667.